Athersys, Inc. NASDAQ:ATHX

Founder-led company

Athersys stock price today

$0.026
+0.01
+92.59%
Financial Health
0
1
2
3
4
5
6
7
8
9

Athersys stock price monthly change

-41.91%
month

Athersys stock price quarterly change

-95.37%
quarter

Athersys stock price yearly change

-98.29%
year

Athersys key metrics

Market Cap
N/A
Enterprise value
6.19M
P/E
-0.15
EV/Sales
1.17
EV/EBITDA
0.85
Price/Sales
2.08
Price/Book
-0.66
PEG ratio
N/A
EPS
-2.01
Revenue
N/A
EBITDA
-40.69M
Income
-37.38M
Revenue Q/Q
-100%
Revenue Y/Y
-98.65%
Profit margin
-1125.62%
Oper. margin
-1607.58%
Gross margin
43.79%
EBIT margin
-1607.58%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Athersys stock price history

Athersys stock forecast

Athersys financial statements

Athersys, Inc. (NASDAQ:ATHX): Profit margin
Dec 2022 32K -12.40M -38762.5%
Mar 2023 0 -8.28M
Jun 2023 49K -12.92M -26375.51%
Sep 2023 0 -3.77M
Athersys, Inc. (NASDAQ:ATHX): Analyst Estimates
2025 21.3M -8.36M -39.26%
  • Analysts Price target

  • Financials & Ratios estimates

Athersys, Inc. (NASDAQ:ATHX): Debt to assets
Dec 2022 27731000 51.58M 186.01%
Mar 2023 21632000 52.64M 243.36%
Jun 2023 10477000 47.89M 457.15%
Sep 2023 7428000 43.82M 589.97%
Athersys, Inc. (NASDAQ:ATHX): Cash Flow
Dec 2022 -11.96M 1.74M 5.47M
Mar 2023 -5.96M 105K -56K
Jun 2023 -4.58M 0 3.26M
Sep 2023 -3.84M 122K 2.94M

Athersys alternative data

Athersys, Inc. (NASDAQ:ATHX): Employee count
Aug 2023 24
Sep 2023 24
Oct 2023 24
Nov 2023 24
Dec 2023 24
Jan 2024 24
Feb 2024 24
Mar 2024 24
Apr 2024 24
May 2024 24
Jun 2024 24
Jul 2024 24

Athersys other data

12.97% -4.19%
of ATHX is owned by hedge funds
1.34M -329.25K
shares is hold by hedge funds

Athersys, Inc. (NASDAQ:ATHX): Insider trades (number of shares)
Period Buy Sel
Mar 2022 132800 0
Nov 2022 100000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
CAMARDO DANIEL A. director, officer: CEO
Common Stock 100,000 $0.55 $55,000
Purchase
CAMARDO DANIEL A. director, officer: CEO
Common Stock 132,800 $0.77 $102,256
Option
LEHMANN WILLIAM JR officer: Interim .. Stock Option (right to purchase) 5,000 $1.28 $6,400
Option
LEHMANN WILLIAM JR officer: Interim .. Common Stock 5,000 $1.28 $6,400
Purchase
KOLA ISMAIL director
Common Stock 85,000 $0.96 $81,685
Purchase
MACLEOD IVOR officer: Chief Financial Officer
Common Stock 15,000 $1.18 $17,700
Option
LEHMANN WILLIAM JR officer: Interim .. Stock Option (right to purchase) 5,000 $1.28 $6,400
Option
LEHMANN WILLIAM JR officer: Interim .. Common Stock 5,000 $1.28 $6,400
Sale
LEHMANN WILLIAM JR officer: Interim .. Common Stock 30,000 $1.41 $42,300
Sale
HARRINGTON JOHN J director, officer.. Common Stock 11,981 $1.47 $17,612
Thursday, 16 November 2023
businesswire.com
Tuesday, 17 October 2023
InvestorPlace
Monday, 28 August 2023
PennyStocks
Friday, 25 August 2023
PennyStocks
Friday, 18 August 2023
InvestorPlace
Monday, 31 July 2023
Business Wire
Monday, 10 April 2023
Business Wire
Thursday, 2 February 2023
Business Wire
Tuesday, 15 November 2022
Seeking Alpha
Friday, 11 November 2022
Business Wire
Tuesday, 25 October 2022
Business Wire
Wednesday, 5 October 2022
Seeking Alpha
Tuesday, 4 October 2022
Business Wire
Friday, 30 September 2022
Business Wire
Monday, 26 September 2022
PennyStocks
Friday, 23 September 2022
PennyStocks
Monday, 19 September 2022
InvestorPlace
Monday, 12 September 2022
InvestorPlace
Thursday, 11 August 2022
Seeking Alpha
Thursday, 28 July 2022
PennyStocks
Monday, 6 June 2022
PennyStocks
Monday, 23 May 2022
Zacks Investment Research
Friday, 20 May 2022
Benzinga
Monday, 16 May 2022
PennyStocks
Wednesday, 11 May 2022
InvestorPlace
Friday, 6 May 2022
PennyStocks
Wednesday, 4 May 2022
Seeking Alpha
Monday, 2 May 2022
Business Wire
Thursday, 21 April 2022
PennyStocks
Monday, 18 April 2022
Seeking Alpha
  • What's the price of Athersys stock today?

    One share of Athersys stock can currently be purchased for approximately $0.03.

  • When is Athersys's next earnings date?

    Unfortunately, Athersys's (ATHX) next earnings date is currently unknown.

  • Does Athersys pay dividends?

    No, Athersys does not pay dividends.

  • What is Athersys's stock symbol?

    Athersys, Inc. is traded on the NASDAQ under the ticker symbol "ATHX".

  • What is Athersys's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Athersys?

    Shares of Athersys can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Athersys's key executives?

    Athersys's management team includes the following people:

    • Mr. Ivor Macleod CPA, M.B.A. Chief Financial Officer & Principal Accounting Officer(age: 63, pay: $587,210)
    • Dr. John J. Harrington Co-Founder, Chief Scientific Officer, Executive Vice President & Director(age: 58, pay: $534,860)
    • Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA Pres, Chief Operating Officer, Sec. & Interim Chief Executive Officer(age: 59, pay: $533,600)
  • Is Athersys founder-led company?

    Yes, Athersys is a company led by its founder Dr. John J. Harrington.

  • How many employees does Athersys have?

    As Jul 2024, Athersys employs 24 workers.

  • When Athersys went public?

    Athersys, Inc. is publicly traded company for more then 18 years since IPO on 12 Jun 2007.

  • What is Athersys's official website?

    The official website for Athersys is athersys.com.

  • Where are Athersys's headquarters?

    Athersys is headquartered at 3201 Carnegie Avenue, Cleveland, OH.

  • How can i contact Athersys?

    Athersys's mailing address is 3201 Carnegie Avenue, Cleveland, OH and company can be reached via phone at +216 4319900.

Athersys company profile:

Athersys, Inc.

athersys.com
Exchange:

NASDAQ

Full time employees:

24

Industry:

Biotechnology

Sector:

Healthcare

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

3201 Carnegie Avenue
Cleveland, OH 44115-2634

CIK: 0001368148
ISIN: US04744L2051
CUSIP: 04744L106